Science journalism · Not medical advice Regulatory window · PCAC review in 42 days

Peptide reference

CK2-18

CK2-18

In vitro

How it works

A synthetic peptide targeting casein kinase 2 (CK2), a constitutively active serine/threonine kinase implicated in cell survival and proliferation signalling. The interest is oncological — CK2 is overexpressed in several cancers. Research into CK2 inhibitor peptides as potential cancer therapeutics is early-stage. This compound is on the PCAC docket, which is unusual given its primarily oncological research context. Human data doesn't exist in a completed trial form.

FDA status
No FDA approval. Under PCAC July 23–24 2026 review for potential 503A bulk substance listing.
WADA status
Not applicable
Route
subcutaneous injection (research)

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

No articles yet on CK2-18

This peptide is on the PCAC review docket but hasn't been covered in depth yet. New research coverage drops regularly — join the waitlist to be first to know.